Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Treatment

FDA Officials Discuss Overhauling Agency In NEJM Perspective
"The FDA as a Public Health Agency," New England Journal of Medicine: In the perspective, FDA Commissioner Margaret Hamburg and Joshua Sharfstein, principal deputy commissioner of the agency, provide "a broad overview" of how they plan to "embrace" the agency"s mission to protect the public"s health. Hamburg and Sharfstein discuss their plans to work with other U.S. agencies, such as NIH, CDC and CMS, as well as challenges posed by globalization. In addition, they write that they will work to improve transparency at FDA (Hamburg/Sharfstein, NEJM, 5/26).
generic viagra online
Genes From Man's Best Friend May Help In The Search For A Cure For Brain Cancer
Pinpointing the genes involved in human brain cancer can be like looking for a needle in a haystack, and sometimes the needle you find may not be the right one. By comparing human and canine genomes, researchers at North Carolina State University have discovered that a gene commonly believed to be involved in meningiomas-tumors that affect the meninges, or thin covering, of the human brain and account for one out of four adult brain tumors -may not be as key for tumor formation as previously thought, and they"ve narrowed the search for the real culprit.
News of the day
Pelleve Receives FDA Clearance For The Treatment Of Mild To Moderate Facial Wrinkles
Ellman International, Inc. announced that the Food and Drug Administration (FDA) has granted clearance to Pelleve(TM), a skin tightening system for the non-ablative treatment of mild to moderate facial wrinkles and rhytids for skin phototypes I-IV. The clearance was granted based on clinical data demonstrating that a single treatment with the high frequency radiowave device can safely and effectively tighten and improve the appearance of skin on the face through six months.
Mental Health

Provectus Completes Patient Accrual In Phase 2 Trial Of PV-10 For Metastatic Melanoma

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company has completed patient accrual and initial PV-10 treatment in its Phase 2 trial of PV-10 for metastatic melanoma. The study involved treatment of 80 subjects with Stage III or Stage IV metastatic melanoma. Dr. Craig Dees, PhD, CEO of Provectus said, "It is gratifying to have reached our patient enrollment objective in the Phase 2 trial of PV-10 for metastatic melanoma and we are pleased with the interim efficacy and safety results that have been achieved and reported on the first 20 patients enrolled in the trial. Completion of the enrollment phase of the trial brings us another step closer in our efforts to find a treatment that may help the estimated 120,000 patients in the U.S. alone who are afflicted with this devastating disease. With an estimated 48,000 global deaths having occurred last year from Stage III or Stage IV melanoma, we remain focused on furthering our work aimed at developing a safe and effective treatment. We look forward to communicating detailed Phase 2 interim results at the American Society of Clinical Oncology (ASCO) Scientific Program on June 1, 2009 in Orlando, Florida." He continued, "Also noteworthy is that even though this phase of the trials has concluded, our investigators have requested that they be allowed to treat more patients. Therefore, we are implementing a compassionate use program for melanoma so patients in need can continue to obtain access to PV-10 while we pursue regulatory approval in the U.S. and abroad." The primary objective of the Phase 2 study is to investigate the effectiveness of intralesional (IL) PV-10 for locoregional treatment of metastatic melanoma. The study also includes assessment of response in untreated bystander lesions following intralesional injection of PV-10 into treated lesions. Additional objectives of the trial are to determine the safety profile of PV-10 following intralesional injection, and assess the pharmacokinetic profile of PV-10 in the bloodstream following intralesional injection. The Phase 2 study is an interventional, open-label, multicenter, single group assignment safety/efficacy study. To accurately reflect anticipated clinical use, repeat dosing of lesions not exhibiting complete response is allowed at the investigator"s discretion several times following initial treatment. Subjects are followed for 52 weeks following initial treatment with PV-10. About PV-10 PV-10 is a proprietary, injectable formulation of Rose Bengal, a compound that has been in use for nearly thirty years by ophthalmologists and optometrists to assess damage to the eye. It has also been used to detect ailments of the liver. Rose Bengal has an established safety history, a short half-life in the bloodstream, and is excreted via the liver and kidneys. Provectus has discovered a novel use for Rose Bengal based on the observation that it is selectively toxic to cancer calls via a process called chemoablation whereby cells undergo a form of cell death that mimics both features of necrosis and apoptosis. Provectus Pharmaceuticals, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009